SEC Filing Summary: Ekso Bionics Holdings, Inc. (10-K)
Business Context and Reporting Period
Company: Ekso Bionics Holdings, Inc. (Ticker: EKSO)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Ekso Bionics designs, develops, and markets robotic exoskeletons for healthcare (Enterprise Health) and individual mobility (Personal Health). Key products include the EksoNR (rehabilitation), Ekso Indego Therapy (rehabilitation), and Ekso Indego Personal (community mobility). The company operates as a single segment with two markets: Enterprise Health and Personal Health.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $12.8 million | $17.9 million |
| Gross Profit | $6.8 million | $9.5 million |
| Gross Margin | 53% | 53% |
| Net Loss | $(11.7) million | $(11.3) million |
| Cash and Restricted Cash (End of Period) | $1.2 million | $6.5 million |
| Working Capital | $5.4 million | $11.3 million |
| Accumulated Deficit | $(262.4) million | $(250.5) million |
Debt Obligations: As of December 31, 2025, the company held a $2.0 million secured promissory note from B. Riley Commercial Capital (maturing September 2026 or upon qualified financing) and a $2.2 million unsecured promissory note to Parker Hannifin Corporation.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 29% to $12.8 million, primarily driven by a decrease in Enterprise Health device sales volume in the EMEA region. This was partially offset by increased Personal Health device sales in the Americas.
- Operating Expenses: Total operating expenses remained relatively flat (up 1% to $20.2 million). Sales and marketing and R&D expenses decreased due to headcount reductions and Employee Retention Credits (ERC), while General and Administrative expenses increased 14% due to higher legal/audit costs and impairment losses.
- Impairment Charges: The company recorded a $0.6 million impairment loss on its trade name intangible asset and a $0.2 million impairment on an intellectual property asset due to the termination of a licensing agreement with Vanderbilt University.
- Foreign Exchange: The company recognized a $2.0 million unrealized gain on foreign exchange in 2025, compared to a $1.0 million loss in 2024.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With only $1.2 million in cash as of year-end and significant operating losses, the company estimates its cash will fund operations only until the end of the second quarter of 2026 without additional financing.
Strategic Transaction (Business Combination): On February 15, 2026, the company entered into a Contribution and Exchange Agreement to combine with Applied Digital Cloud Corporation. Upon closing, the company will be renamed ChronoScale Corporation. The transaction involves issuing approximately 138 million new shares, resulting in legacy shareholders owning approximately 3% of the combined entity. Closing is subject to conditions, including stockholder approval (obtained Feb 20, 2026) and raising at least $15 million in cash.
Recent Financing: In January 2026, the company completed a private placement of Series B Preferred Stock and warrants, raising approximately $5.3 million in net proceeds.
Key Risks:
- Liquidity: Insufficient cash to fund operations beyond Q2 2026 without the Business Combination or new capital.
- Reimbursement: Personal Health growth depends on Medicare (CMS) reimbursement processes, which remain complex and subject to appeals.
- Regulatory: Pending EU MDR certification updates for manufacturing location changes may delay shipments to the European Union until H1 2026.
Investor Verification Checklist
- Business Combination Status: Verify the timeline and conditions for the closing of the Applied Digital Cloud transaction, specifically the requirement to raise $15 million in cash.
- Liquidity Runway: Confirm the sufficiency of the $5.3 million private placement proceeds combined with existing cash to bridge operations until the Business Combination closes or further financing is secured.
- Dilution Impact: Assess the impact of the proposed issuance of 138 million shares on existing shareholder equity (approx. 97% ownership by the new entity).
- EU Regulatory Compliance: Monitor the status of the updated CE certificate required for shipping products manufactured in California to the EU.
- Debt Covenants: Review the terms of the B. Riley Promissory Note, including the maturity date and conversion features tied to a "Qualified Financing."